<DOC>
	<DOC>NCT02528903</DOC>
	<brief_summary>This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics (PK) of MHAB5553A.</brief_summary>
	<brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Signed informed consent form (ICF) Body mass index (BMI) between 18 and 32 kg/m2, inclusive Weight 40100 kg In good health, determined by no clinically significant findings from medical history, 12lead ECG, and vital signs Clinical laboratory evaluations should be within reference range for the test, unless deemed not clinically significant by the investigator and sponsor at screening Willing to abstain from using drugs of abuse while enrolled in the study Willing and able to comply with protocolspecified criteria in regard to contraceptive protection Able to comply with the study protocol, in the investigator's judgment History or clinically significant manifestations of metabolic, hepatic, renal, hematologic, immunodeficiency, pulmonary, cardiovascular, gastrointestinal, urologic, neurologic, or psychiatric disorders History of anaphylaxis, hypersensitivity or drug allergies, unless approved by the investigator and sponsor History or presence of an abnormal ECG, which, in the investigator's or sponsor's opinion, is clinically significant (including evidence of previous acute myocardial infarction, complete left bundle branch block, seconddegree heart block, or complete heart block) History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to screening visit or hard drugs (such as cocaine, phencyclidine [PCP], and crack) within 1 year prior to screening Current tobacco smokers (positive history within 3 months before initiation of dosing on Day 1), or those with positive cotinine test at checkin Positive drug screen at screening or at checkin Positive pregnancy test result at screening or Day 1 or breast feeding during the study Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe enrollment in and completion of the study Unwillingness to comply or other conditions that, in the opinion of the investigator, would interfere with the ability to comply with the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>